BPC-157 vs Dihexa
Side-by-Side Comparison
| Attribute | Bpc 157 | Dihexa |
|---|---|---|
| Category | Healing & Recovery | Nootropic / Cognitive |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and... | Dihexa activates the hepatocyte growth factor receptor (c-Met) by binding to HGF molecules and dimerizing with endogenous HGF to form a functional ligand, producing more physiological signaling than... |
| Evidence Rating | C — Phase I–II Clinical Trials | F — No Regulatory Activity |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Research-only / Preclinical. CAUTION: foundational paper retracted April 2025 for data fabrication. |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | No human safety data exists whatsoever; Short-duration animal studies report no apparent toxicity at research dosages |
| Route | Subcutaneous (preferred), Intramuscular, or Oral | Oral (sublingual/capsule) or Intranasal |
| Dose Range | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials | Oral: 0.5–2 mg/day; Intranasal: 0.5–1.5 mg/day |
| Frequency | Once daily | Once daily |
| Molecular Weight | ~1419.5 g/mol | ~507.6 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | Unknown; lipophilic, orally active |
Overview
BPC-157 and Dihexa are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
Dihexa — Mechanism & Evidence
Dihexa (PNB-0408) is a synthetic small molecule derived from angiotensin IV, developed at Washington State University by the Harding lab. It is a hepatocyte growth factor (HGF) mimetic that activates HGF/c-Met signaling in the brain, promoting synaptogenesis, neuroplasticity, and neuronal survival. Unlike large HGF proteins, Dihexa has good oral bioavailability and crosses the blood-brain barrier. In APP/PS1 Alzheimer's model mice, Dihexa activated the PI3K/AKT pathway, reduced neuroinflammation, and rescued cognitive impairment. It has also shown promise for peripheral nerve regeneration and protection against chemical ototoxicity. No human clinical trials exist.
Key claims: Rescues cognitive impairment in Alzheimer's model; Promotes peripheral nerve regeneration; Protects against chemical ototoxicity.
Shared Research Applications
These peptides target different research areas. BPC-157 focuses on Injury Recovery, Gut Health, while Dihexa targets Cognitive Enhancement.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Dihexa: No human safety data exists whatsoever Short-duration animal studies report no apparent toxicity at research dosages Potent HGF/c-Met activation raises theoretical oncological concerns (c-Met pathway involved in tumor progression)
Related Products
Related Research News
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
BPC-157 Shelf Life: Lyophilized vs Reconstituted Stability Guide
BPC-157 has a finite shelf life that varies by form and storage. Lyophilized powder lasts 12-18 months refrigerated or 24+ months frozen, while reconstituted solution holds for about 28 days under refrigeration. Factors like temperature, light, and handling influence stability, and researchers should watch for signs of degradation to ensure reliable results.
BPC-157 + TB-500 Peptide Blend: Research on Healing and Repair
The BPC-157 and TB-500 peptide blend draws attention in research for potential synergy in tissue repair, angiogenesis, and reducing inflammation. BPC-157, a 15-amino-acid synthetic peptide, interacts with growth factors in preclinical models. TB-500, a 43-amino-acid analog of Thymosin Beta-4, supports cell migration and regeneration. Studies explore their roles in wound healing, tendon recovery, and more.